NCT07082764View on ClinicalTrials.gov

Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

December 15, 2026

Conditions
Chemotherapy Induced Peripheral Neuropathy
Interventions
DRUG

Brimonidine gel

TAR-0520 gel

OTHER

No intervantion

No treatment

Trial Locations (1)

13009

Institut Paoli-Calmettes, Marseille

All Listed Sponsors
lead

Tarian Pharma

INDUSTRY